ImmunoPrecise Antibodies Ltd.

IPA

CA45257F2008

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:00:01 17/07/2024 am IST			5-day change	1st Jan Change
0.98 ^USD	+0.31%		-1.01%	-42.69%

16/07	ImmunoPrecise Antibodies Ltd. announced that it expects to receive CAD 3 million in funding from Yorkville Advisors Global LP	CI
27/06	ImmunoPrecise Antibodies Ltd. Appoints Kristin Taylor as Permanent Chief Financial Officer	CI

ImmunoPrecise Antibodies Ltd Reports on its Annual Meeting of Shareholders

November 17, 2023 at 03:43 am IST

On November 16, 2023, ImmunoPrecise Antibodies Ltd announced the results of voting at its Annual General Meeting held on November 9, 2023. Since no further discussions have occurred between Ingalls & Snyder, LLC and the Company, the campaign is considered to have been withdrawn.

Latest news about ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. announced that it expects to receive CAD 3 million in funding from Yorkville Advisors Global LP	16/07	CI
ImmunoPrecise Antibodies Ltd. Appoints Kristin Taylor as Permanent Chief Financial Officer	27/06	CI
ImmunoPrecise Antibodies Unit, PGxAI to Develop AI Model to Predict Treatment Responses	25/06	MT
Immunoprecise Antibodies Ltd. Announces the Commercial Release of Lens Ai API, Hereafter Referred to as the `Software', by Its Subsidiary, Biostrand	10/06	CI
ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform	22/04	CI
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	12/04	CI
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024	14/03
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	14/03	CI
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	06/03	CI
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	06/03	CI
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	06/03	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	14/12	CI
Transcript : ImmunoPrecise Antibodies Ltd., Q2 2024 Earnings Call, Dec 14, 2023	14/12
Top Premarket Gainers	13/12	MT
Private Payrolls Increased Less Than Expected in November as US Equity Futures Rise Pre-Bell	06/12	MT
Jobs Data in Focus as Exchange-Traded Funds, Equity Futures Lean Higher Pre-Bell Wednesday	06/12	MT
Top Premarket Decliners	06/12	MT
ImmunoPrecise Antibodies Plans Underwritten Offering of Common Stock; Shares Fall Pre-Bell	06/12	MT
ImmunoPrecise Antibodies Ltd. Announces Board Changes	27/11	CI
ImmunoPrecise Antibodies Ltd Reports on its Annual Meeting of Shareholders	17/11	CI
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology	20/23/20	CI
ImmunoPrecise Antibodies Names Kristin Taylor Interim Finance Chief	19/23/19	MT
ImmunoPrecise Antibodies Announces CFO Transition	19/23/19	CI
Transcript : ImmunoPrecise Antibodies Ltd., Q1 2024 Earnings Call, Sep 14, 2023	14/23/14
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the First Quarter Ended July 31, 2023	14/23/14	CI

Chart ImmunoPrecise Antibodies Ltd.

Duration

Period

More charts

Company Profile

ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for ImmunoPrecise Antibodies Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.98 USD

Average target price

7 USD

Spread / Average Target

+614.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMUNOPRECISE ANTIBODIES LTD.	-42.69%	2.57Cr
CSL LIMITED	+7.81%	10TCr
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	4.22TCr
BIOGEN INC.	-13.04%	3.23TCr
UCB	+80.80%	2.98TCr
BIOMARIN PHARMACEUTICAL INC.	-10.92%	1.61TCr
INCYTE CORPORATION	+1.93%	1.44TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	1.2TCr
ALTEOGEN INC.	+177.16%	1.07TCr
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	889.02Cr

Biopharmaceuticals